Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Sotagliflozin Outperforms Dapagliflozin for Reducing Salt-Sensitive Hypertension and Kidney Injury in Rats

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney-protective effects. In the kidney, SGLT2 reabsorbs approximately 97% of filtered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1 reabsorbs the remainder in the S3 segment. In research conducted in rats, investigators found that dual inhibition of SGLT1 and SGLT2 more effectively reduces salt-sensitive hypertension and kidney injury than SGLT2 inhibition alone. The findings will be presented at ASN Kidney Week 2025 November 5-9.

November 7, 2025


November 8 2025

November 7 2025

November 6 2025

November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025